0001193125-26-064230
SEC filingNo financial data available as Notes section was not provided in the input.
Novanta Inc. describes itself as a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers (OEMs) a competitive advantage. The company combines deep proprietary technology expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It was founded in 1968 as General Scanning and changed its name to Novanta Inc. in May 2016.
Novanta has two reportable segments: Automation Enabling Technologies and Medical Solutions. For the year ended December 31, 2025, Automation Enabling Technologies generated $500.8 million in revenue (51.1% of total) with a gross profit margin of 47.8% and operating profit of $114.5 million. Medical Solutions generated $479.8 million in revenue (48.9% of total) with a gross profit margin of 41.6% and operating profit of $51.2 million. The Automation Enabling Technologies segment designs and manufactures laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and air bearing spindles. The Medical Solutions segment designs and manufactures medical insufflators and endoscopic pumps and related disposables, imaging, identification and RFID solutions, advanced motion control solutions, light engines, and integrated operating room technologies.
Key product lines include Laser Beam Steering and Scanning Solutions (optical scanning and scan heads), Laser Sources (diode, DPSS, CO2), Robotic and Precision Motion (position sensors, torque sensors, motors, drives), Robotic end-of-arm tooling (tool changers, force torque sensors), Air Bearing Spindles, Medical Insufflators and Endoscopic Pumps, Imaging, Identification and RFID Solutions, Advanced Motion Control Solutions (customized subsystems), Light Engines (laser-based light engines for DNA sequencing), and Integrated operating room technologies (imaging management, wireless video, touch panels).
The vast majority of products are sold to OEM customers, primarily through a direct highly technical sales force, with some indirect sales through resellers and distributors. Application centers around the world support customer integration. Novanta has a diverse customer base; two OEM customers in the medical end market accounted for approximately 12% and 11% of consolidated revenue in 2025. One OEM customer represented 10% in 2024 and 2023. Once products are designed into an OEM's system, significant barriers to supplier changes exist, especially in medical markets.
Novanta encounters strong competition across all markets and technologies. Competitors range from large global organizations to small specialized firms. Success depends on technology advances, product performance, price-for-performance, throughput, total cost of ownership, quality, application knowledge, customer service, speed to market, and geographical presence. The company believes its breadth of technologies provides competitive advantages.
Novanta's strategy focuses on sustainable profitable growth through: disciplined focus on diversified OEM platforms; improving business mix toward medical sales via new products, key account management, and acquisitions; increasing penetration of advanced industrial applications; broadening proprietary technologies through R&D and acquisitions; expanding sales channels; strengthening operational performance with lean manufacturing and regionalization; and advancing a people-first culture.
As of December 31, 2025, Novanta employed approximately 3,000 people, with about 600 engineers. The workforce is 36% in the US, 55% in Europe, and 9% in Asia. The company emphasizes employee engagement through surveys, with a satisfaction score at 97% of benchmark in February 2025. It provides training via Novanta University, and promotes safety, inclusion, and development through ERGs, tuition reimbursement, and the Novanta Growth System.
No data available because the Notes to Financial Statements were not included in the provided document. The input only contained a table of contents and introductory text.
No data available.
No data available.
No segment data was disclosed in the provided section.